


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药  
*SihuanPharm*

**Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock code: 0460)**

## **VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE**

This is a voluntary announcement made by Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**”).

Reference is made to the announcement of the Company dated 28 March 2021 in relation to the proposed on-market repurchase of shares of the Company (the “**Shares**”) and the announcements dated 8 July, and 16 and 17 September 2021 respectively in relation to on-market share repurchases made by the Company pursuant to the general mandate to repurchase (the “**Repurchase Mandate**”) Shares granted by the shareholders of the Company at the annual general meeting held on 30 June 2021.

The board of directors of the Company (the “**Board**”) announces that, on 20 September 2021, the Company repurchased, pursuant to the Repurchase Mandate, a total of 1,320,000 Shares on market at an average price of HK\$2.0744 per Share (the “**Share Repurchase**”).

The aggregate purchase price paid (excluding commission and other expenses) for the Share Repurchase was approximately HK\$2,738,208. The repurchased Shares represent approximately 0.03% of the total number of issued Shares as at the date of this announcement. The Company will subsequently cancel the repurchased Shares as a result of the Share Repurchase. Including the Shares repurchased by the Company on 8 July, and 16, 17 and 20 September 2021, the Company has repurchased a total of 8,620,000 Shares, representing approximately 0.09% of the total number of issued Shares as at the date of this announcement, in reliance on the Repurchase Mandate.

The financial position of the Company is solid and healthy currently. The Board believes the Share Repurchase and subsequent cancellation of the repurchased Shares could enhance the value of the Shares thereby improving the return to shareholders of the Company. In addition, the Board believes that the Share Repurchase reflects the Company’s confidence in its long term business prospects and would ultimately benefit the Company and is in the interests of the Company and the shareholders of the Company as a whole. The Company may make further share repurchase depending on market conditions.

Shareholders and potential investors should note that any repurchase may be done subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the securities of the Company.

By Order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 20 September 2021

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.*